Source: FDA label
| Registered trials | 147 |
|---|---|
| Brand names | Glatopa |
Mechanism of Action
12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis, a condition induced in animals through immunization against central nerv
Key takeaways
- Glatiramer is approved to treat relapsing forms of multiple sclerosis, including clinically isolated syndrome and relapsing-remitting disease.
- It is marketed under the brand name Glatopa and carries no boxed warning.
- More than 147 trials registered on clinicaltrials.gov have studied glatiramer or compared it against other MS therapies.
- Injection site reactions and MS relapse are among the most frequently reported issues in real-world safety reports.
What glatiramer is
Glatiramer acetate is a disease-modifying therapy for multiple sclerosis. Researchers do not fully understand how it works, but it is thought to modify immune processes involved in the disease. That hypothesis is supported by animal studies of a condition that mimics how MS develops in the nervous system.
What glatiramer is approved for
Glatiramer, sold as Glatopa, is approved for relapsing forms of multiple sclerosis in adults. This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The label carries no boxed warning.
What the evidence shows
Glatiramer has been studied across 147 registered trials. One phase 3 trial compared two doses of fingolimod against glatiramer (marketed as Copaxone) but was terminated. A completed phase 2 trial examined rituximab induction therapy followed by glatiramer, and a completed phase 4 trial compared fingolimod outcomes in newly treated patients versus those switching from a first-line therapy.
Reported side effects
Safety reports for glatiramer are dominated by injection-related and disease-related events. These figures reflect report counts, not confirmed incidence or causation. The most frequent reports involve MS relapse (5,340) and injection site pain (5,339), followed by reports of the drug being ineffective (4,183) and injection site reactions (3,585). Fatigue (3,418), MS itself (3,253), dyspnoea (3,024), and injection site erythema (2,676) also appear frequently in these reports.
FAQ
What is glatiramer used for?
Glatiramer is approved to treat relapsing forms of multiple sclerosis in adults. This covers clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is sold under the brand name Glatopa.
How does glatiramer work?
The exact mechanism is not fully understood, but glatiramer is thought to modify immune processes linked to multiple sclerosis. This idea comes from studies of an animal condition that resembles how MS develops in the nervous system.
Does glatiramer have a boxed warning?
No, the label for glatiramer does not carry a boxed warning.
What are the most commonly reported side effects of glatiramer?
The most frequently reported issues include injection site pain and reactions, MS relapse, fatigue, and dyspnoea. These come from safety reports and reflect report counts, not confirmed rates or proof that glatiramer caused them.
How much clinical research exists on glatiramer?
More than 147 trials involving glatiramer are registered on clinicaltrials.gov. These include studies comparing it with other MS therapies such as fingolimod and rituximab across different phases and patient populations.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: DailyMed label (Glatopa) FAERS adverse event reports ClinicalTrials.gov
Updated 2026-08-03